GlassScriptPhysician profile
Laura Akright
NPI 1568548204
$5,918.31
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,117 · 2020: $1,503 · 2021: $860 · 2022: $544 · 2023: $770 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $645.19 | 2019-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $640.63 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $606.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $533.83 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $368.16 | 2019-2024 | |
| Dexcom, INC. | $338.94 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $269.08 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $256.88 | 2019 | |
| Abbvie INC. | $248.88 | 2019-2023 | Synthroid |
| Lilly USA, LLC | $218.80 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $208.58 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $200.19 | 2019-2021 | |
| Zealand Pharma US, INC. | $198.64 | 2020-2021 | |
| Insulet Corporation | $191.43 | 2019-2020 | |
| Valeritas, INC. | $162.77 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $139.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.30 | 2020-2022 | |
| Ibsa Pharma INC. | $102.25 | 2019-2023 | Tirosint, Licart |
| Medtronic, INC. | $94.45 | 2022 | |
| Merck Sharp & Dohme LLC | $70.00 | 2022 | |
| Corcept Therapeutics | $47.31 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $43.08 | 2021-2023 | |
| Medtronic Minimed, INC. | $42.91 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $27.08 | 2020 | |
| Hologic Sales and Service, LLC | $24.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.18 | 2023 | |
| Horizon Therapeutics Plc | $18.54 | 2023 | Tepezza |
| Intuity Medical INC | $18.09 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cequr Corporation | $15.69 | 2023 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $15.07 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $12.40 | 2019 | |
| Shire North American Group INC | $11.90 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Akright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.